Trends in Diagnosis and Treatment of Metastatic Cancer in the United States
- 27 September 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal of Clinical Oncology
- Vol. 44 (11), 572-579
- https://doi.org/10.1097/coc.0000000000000866
Abstract
Objectives: Metastatic cancer has historically been considered fatal; however, there is a paucity of evidence characterizing the epidemiology of incidence, treatment, and outcomes in these patients. Materials and Methods: Incidence rates, annual percent change (APC), descriptive epidemiological statistics, and odds ratios for survival were calculated using registry data from the Surveillance, Epidemiology, and End Results (SEER) and the National Cancer Database (NCDB), 1998 to 2015. Results: There were a total of 1,055,860 patients with metastatic cancer. The most frequent primary cancers were lung (42.6%), colorectal (9.5%), and ovarian (5.5%). Metastatic lung and colorectal cancer incidence decreased, APC: −1.57 (PPP=0.001). The use of local therapies decreased for almost all sites, and the use of systemic therapies increased across multiple sites: single-agent chemotherapy in kidney (2.54% increase/year), female breast (1.14% increase/year), and prostate cancer (1.08% increase/year); multiagent chemotherapy, most notably in pancreas (2.23% increase/year), uterus (1.81% increase/year), and colorectal cancer (1.54% increase/year). Increased utilization of immunotherapy was observed across the majority of sites, most notably in melanoma (2.14% increase/year). Patients diagnosed from 2006 to 2010 had 17.4% higher odds of surviving at least 60 months compared with 1998 to 2002. Conclusions: In this study, metastatic disease has been shown to have unique epidemiological patterns, and survival has improved. Continued research on metastatic disease is important in understanding and addressing the distinct health concerns of this population.Keywords
This publication has 53 references indexed in Scilit:
- Effect of Three Decades of Screening Mammography on Breast-Cancer IncidenceThe New England Journal of Medicine, 2012
- Overview of the Surveillance, Epidemiology, and End Results Database: Evolution, Data Variables, and Quality AssuranceCurrent Problems in Cancer, 2012
- Epidemiology of Central Nervous System MetastasesProgress in Neurological Surgery, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaThe New England Journal of Medicine, 2011
- Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based studyGut, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Epidemiology of colorectal liver metastasesSurgical Oncology, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- The Will Rogers PhenomenonThe New England Journal of Medicine, 1985